Skip Navigation LinksHome > December 2012 - Volume 31 - Issue 12 > Antiretroviral Treatment Strategies in Highly Treatment Expe...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31826fd3e7
HIV Reports

Antiretroviral Treatment Strategies in Highly Treatment Experienced Perinatally HIV-infected Youth

Wong, Frances L. PharmD, MEd, MPH, BCPS*; Hsu, Alice J. PharmD, BCPS, AQ-ID; Pham, Paul A. PharmD, BCPS†‡; Siberry, George K. MD, MPH§; Hutton, Nancy MD; Agwu, Allison L. MD, ScM

Supplemental Author Material
Collapse Box

Abstract

Background: There is limited information on antiretroviral (ARV) regimens and outcomes in perinatally HIV (PHIV)-infected youth. Substantial drug resistance after long-term ARV use and nonadherence hinder efforts to design suppressive regimens for PHIV-infected youth. This study compares clinical outcomes by expected activity of the prescribed ARV regimens.

Methods: A retrospective cohort study of 13- to 24-year-old PHIV-infected youth on stable ARV regimens for ≥6 months was conducted at a pediatric HIV clinic. ARV regimens were retrospectively categorized as optimal or suboptimal based on accumulated genotypic resistance before study regimen initiation.

Results: Fifty-two patients with similar baseline characteristics met inclusion criteria (21 optimal and 31 suboptimal regimens). Patients receiving optimal regimens had significantly higher increases in CD4 than those given suboptimal regimens by week 48 of treatment (+62 versus +8 cells/mm3, respectively; P = 0.04) and by the end of study period (+93 versus −1 cells/mm3, respectively; P = 0.03). There were no significant differences between the groups in decline of viral load, frequency of opportunistic infections or hospitalizations or accumulation of resistance mutations. Overall, 60% of the optimal and 45% of the suboptimal groups had nonadherence during the study regimen (P = 0.3).

Conclusions: PHIV-infected youth receiving optimal regimens had greater CD4 improvements but no difference in virologic outcomes compared with those receiving suboptimal regimens. In a patient population with significant nonadherence, providers must weigh the immunologic benefits of initiating an optimal regimen versus the potential risks of further resistance accumulation limiting future treatment options.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.